Welcome to a new year with the Flemingsberg Science Foundation

It is with great pleasure that we embark on 2024 with a continued work according to the strategic goals that apply for 2022 – 2025, namely to become the obvious establishment alternative in southern Stockholm, to offer a world-class innovation environment and enable test beds for urban societal challenges.

Based on the results of our operations in 2022 and 2023, we are now entering a new phase where we focus more on the market and marketing of Flemingsberg. We can now offer coworking spaces, a Novum in development, ready-to-build land, and a growing city. Additionally, the initiative ATMP Flemingsberg is being launched, along with a broad-based value proposition. With all these factors in place, it is natural for us to take the next step in promoting Flemingsberg.

For the Flemingsberg Science Foundation, the focus is on “work”. This year is about implementing business development initiatives in research infrastructures, through the investment in the establishment office and with the help of associated partners, solving establishment-inhibiting knots and creating a platform for communication of ATMP Flemingsberg, the leading ATMP hub in the Nordic region! It is also about filling the Innovation Station with the right actors and content that creates tomorrow’s stars in the cultural and creative industries, which will also be an important building block in an emerging, attractive city.

We look forward to continuing our journey together with you and hope that you will follow us during 2024.

Johnny Högberg
CEO, Flemingsberg Science Foundation

HappyPaws medical journal concept wins Flemingsberg Science Award

The idea behind HappyPaws is an open platform that provides pet owners power over their pets’ medical records. It would give pet owners a better overview of their animals’ medical histories, from previous visits to the vet to the vaccination status, and allow information to be shared with other users.

Biomedrex Genetics is developing antiviral drugs

“We’re developing a completely new drug to combat viral infections – an antiviral drug – using modern genetic engineering. Our methods are based on the Nobel-winning CRISPR technology that paves the way to new, targeted treatments,” says Theodor Pramer, CEO of Biomedrex Genetics.

Go to Top